Table 3 Neoadjuvant treatment-emergent adverse events (safety set, n = 32)
Adverse event | Any grade | Grades 1–2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Thrombocytopenia, n (%) | 16 (50.0%) | 9 (28.1%) | 4 (12.5%) | 3 (9.4%) |
Hypertension, n (%) | 14 (43.8%) | 5 (15.6%) | 9 (28.1%) | 0 |
Neutropenia, n (%) | 12 (37.5%) | 7 (21.9%) | 4 (12.5%) | 1 (3.1%) |
Leukopenia, n (%) | 11 (34.4%) | 11 (34.4%) | 0 | 0 |
Anorexia, n (%) | 10 (31.4%) | 7 (21.9%) | 3 (9.4%) | 0 |
Proteinuria, n (%) | 9 (28.1%) | 8 (25.0%) | 1 (3.1%) | 0 |
Anemia, n (%) | 8 (25.0%) | 8 (25.0%) | 0 | 0 |
Fatigue, n (%) | 7 (21.9%) | 4 (12.5%) | 3 (9.4%) | 0 |
Oral mucositis, n (%) | 6 (18.8%) | 6 (18.8%) | 0 | 0 |
Vomiting, n (%) | 5 (15.6%) | 5 (15.6%) | 0 | 0 |
Hand-foot syndrome, n (%) | 2 (6.3%) | 1(3.1%) | 1 (3.1%) | 0 |
Elevation of ALT/AST, n (%) | 2 (6.3%) | 2 (6.3%) | 0 | 0 |
Tumor bleeding, n (%) | 1 (3.1%) | 0 | 0 | 1 (3.1%) |